| abstract |
A set of small molecule ER (square figure) biomodulators that kill ER (square figure) positive breast, ovarian and endometrial cancer cells resistant to therapy. These small molecules have greater therapeutic potential due to the greater ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The new compounds not only inhibit the proliferation of cancer cells, but also actually destroy them, preventing tumors from reactivating years later. |